Furthermore, IDH mutations are well-known to be an independent favorable prognostic factor at all stages of glioma progression; for example, the median survival in IDH-mutant GBM is 31 months, over twice as long as the median 15-months survival in the wild-type counterpart (1). This evidence concerns the gene IDH1 and central nervous system cancer.